Article
Bristol Myers' Opdivo extends survival in bladder cancer study
Rating:
0.0
Views:
55
Likes:
1
Library:
1
Bristol Myers Squibb Co said on Tuesday its blockbuster cancer immunotherapy, Opdivo, in combination with chemotherapy improved survival in patients with a type of bladder cancer in a late-stage trial.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value